Addition of low dose acetazolamide as an adjunct in patients undergoing high dose methotrexate is safe and beneficial.
acetazolamide
methotrexate
renal insufficiency
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
22
11
2018
revised:
29
07
2019
accepted:
04
08
2019
pubmed:
14
8
2019
medline:
28
4
2021
entrez:
13
8
2019
Statut:
ppublish
Résumé
High-dose methotrexate (HDMTx) is utilised in central nervous system lymphoma and acute lymphoblastic leukaemia due to its ability to penetrate the blood-brain barrier. Despite its efficacy, nephrotoxicity is a potentially serious toxicity that could also exacerbate other methotrexate-related toxicities and compromise dose intensity. Acetazolamide (AZL) is a carbonic anhydrase inhibitor that causes an increase in bicarbonate excretion and consequently urine alkalinisation. Following occurrences of HDMTx-induced acute kidney injury (AKI) due to inadequate urine alkalinisation at our institution, routine AZL was administered to appropriate patients from 2010 onwards. To analyse the addition of AZL to routine renoprotective measures, given that inadequate urinary alkalinisation is the major risk factor for methotrexate crystal precipitation and prolonged excretion. In addition, since fluid overload is a common consequence of HDMTx treatment, the effect of AZL on fluid balance was also examined. This is a retrospective, single-centred cohort study examining the mitigation of HDMTx-induced toxicities by AZL in 92 patients over a 6-year period. AZL showed a strong trend of preventing either AKI (as per CTCAE version 4.03) or delayed methotrexate elimination (>5 days), especially in males. Furthermore, AZL also resulted in reduced weight gain and fewer episodes of urinary pH <7.0. AZL appeared to diminish the incidence of HDMTx-induced toxicities, including reducing oedema-related weight gain. With mild, preventable hypokalaemia as the only noteworthy toxicity, AZL could be considered as an adjunct to HDMTx patient care.
Sections du résumé
BACKGROUND
High-dose methotrexate (HDMTx) is utilised in central nervous system lymphoma and acute lymphoblastic leukaemia due to its ability to penetrate the blood-brain barrier. Despite its efficacy, nephrotoxicity is a potentially serious toxicity that could also exacerbate other methotrexate-related toxicities and compromise dose intensity. Acetazolamide (AZL) is a carbonic anhydrase inhibitor that causes an increase in bicarbonate excretion and consequently urine alkalinisation. Following occurrences of HDMTx-induced acute kidney injury (AKI) due to inadequate urine alkalinisation at our institution, routine AZL was administered to appropriate patients from 2010 onwards.
AIMS
To analyse the addition of AZL to routine renoprotective measures, given that inadequate urinary alkalinisation is the major risk factor for methotrexate crystal precipitation and prolonged excretion. In addition, since fluid overload is a common consequence of HDMTx treatment, the effect of AZL on fluid balance was also examined.
METHODS
This is a retrospective, single-centred cohort study examining the mitigation of HDMTx-induced toxicities by AZL in 92 patients over a 6-year period.
RESULTS
AZL showed a strong trend of preventing either AKI (as per CTCAE version 4.03) or delayed methotrexate elimination (>5 days), especially in males. Furthermore, AZL also resulted in reduced weight gain and fewer episodes of urinary pH <7.0.
CONCLUSION
AZL appeared to diminish the incidence of HDMTx-induced toxicities, including reducing oedema-related weight gain. With mild, preventable hypokalaemia as the only noteworthy toxicity, AZL could be considered as an adjunct to HDMTx patient care.
Substances chimiques
Antimetabolites, Antineoplastic
0
Acetazolamide
O3FX965V0I
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
357-362Informations de copyright
© 2019 Royal Australasian College of Physicians.
Références
Katzung B, Masters SB, Trevor AJ. Basic and Clinical Pharmacology, 11th edn. New York: McGraw Hill Professional; 2009.
Joerger M, Ferreri AJM, Krähenbühl S, Schellens JHM, Cerny T, Zucca E et al. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 2012; 73: 240-7.
Joerger M, Huitema ADR, van den Bongard HJGD, Baas P, Schornagel JH, Schellens JHM et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006; 62: 71-80.
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512-20.
Schafer N, Glas M, Herrlinger U. Primary CNS lymphoma: a clinician's guide. Expert Rev Neurother 2012; 12: 1197-206.
Roth P, Korfel A, Martus P, Weller M. Pathogenesis and management of primary CNS lymphoma. Expert Rev Anticancer Ther 2012; 12: 623-33.
Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol 2010; 12: 736-44.
Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet 2012; 379: 1984-96.
Prica A, Chan K, Cheung MC. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis. Br J Haematol 2012; 158: 600-7.
Deangelis LM, Hormigo A. Treatment of primary central nervous system lymphoma. Semin Oncol 2004; 31: 684-92.
Welch MR, Omuro A, Deangelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro Oncol 2012; 14: 1304-11.
Xie H, Peereboom DM. Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma. J Clin Oncol 2012; 30: e192-4.
Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E et al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res 2011; 17: 346-52.
Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013; 31: 3061-8.
Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma - a long-term follow-up study. Ann Oncol 2012; 23: 2670-5.
Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 2011; 22: 2080-5.
Joerger M, Huitema ADR, Krähenbühl S, Schellens JHM, Cerny T, Reni M et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102: 673-7.
Abrey LE. Controversies in primary CNS lymphoma. Expert Rev Neurother 2005; 5: 459-64.
Bessell EM, Hoang-Xuan K, Ferreri AJM, Reni M. Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer 2007; 43: 1141-52.
Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 2013; 9: 317-27.
Abrey LE. Hematology. Individualized methotrexate dosing in primary CNS lymphoma. Nat Rev Clin Oncol 2010; 7: 306-7.
O'Brien PC, Seymour JF. Progress in primary CNS lymphoma. Lancet 2009; 374: 1477-8.
Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009; 8: 581-92.
McMillan A, Ardeshna KM, Cwynarski K, Lyttelton M, McKay P, Montoto S et al. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol 2013; 163: 168-81.
Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013; 24: 1385-92.
Korfel A. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Curr Opin Oncol 2011; 23: 436-40.
Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010; 116: 4283-90.
Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011; 12: 1258-66.
O'Rourke K, Morris K, Kennedy GA. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2011; 117: 2579-80; author reply 2580-1.
Salkade PR, Lim TA. Methotrexate-induced acute toxic leukoencephalopathy. J Cancer Res Ther 2012; 8: 292-6.
Christensen AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer 2012; 118: 4321-30.
Lameire N, Kruse V, Rottey S. Nephrotoxicity of anticancer drugs - an underestimated problem? Acta Clin Belg 2011; 66: 337-45.
Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009; 11: 211-5.
Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11: 694-703.
Kintzel PE, Campbell AD, Yost KJ, Brinker BT, Arradaza NV, Frobish D et al. Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate. J Oncol Pharm Pract 2012; 18: 239-44.
Puschett JB. Sites and mechanisms of action of diuretics in the kidney. J Clin Pharmacol 1981; 21: 564-74.
Shamash J, Earl H, Souhami R. Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate. Cancer Chemother Pharmacol 1991; 28: 150-1.